These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 36894804)

  • 1. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X; Li X; Sun P; Li Z; Sun P; Ning S
    BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; ():. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
    Guan R; Zhang N; Deng M; Lin Y; Huang G; Fu Y; Zheng Z; Wei W; Zhong C; Zhao H; Mei J; Guo R
    Int J Surg; 2024 Jul; 110(7):4062-4073. PubMed ID: 38549220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
    Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
    Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
    Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
    J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
    JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.